_id
69104febccc777a4e85d53cb
Ticker
CLNNW
Name
Clene Inc
Exchange
NASDAQ
Address
6550 South Millrock Drive, Salt Lake City, UT, United States, 84121
Country
USA
Sector
Industry
Currency
USD
Website
https://clene.com
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Last Close
0.0022
Volume
92404
Current Price
0.0018
Change
-0.0007
Last Updated
2026-01-02T11:31:25.505Z
Image
data:image/webp;base64,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
Ipo Date
2020-12-31T00:00:00.000Z
Market Cap
646977800
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
15000
Cost Of Revenue
0
Gross Profit
15000
Operating Expenses
5663000
Operating Income
-5648000
Interest Expense
649000
Pretax Income
-8777000
Net Income
-8777000
Eps
-0.8534057569544742
Dividends Per Share
-
Shares Outstanding
0
Income Tax Expense
-
EBITDA
-7763000
Operating Margin
-37653.333333333336
Total Other Income Expense Net
-3129000
Cash
7925000
Short Term Investments
-
Receivables
550000
Inventories
61000
Total Current Assets
12673000
Property Plant Equipment
9580000
Total Assets
22311000
Payables
1369000
Short Term Debt
2043000
Long Term Debt
15785000
Total Liabilities
34668000
Equity
-12357000
Bs_currency_symbol
USD
Depreciation
365000
Change In Working Capital
-420125
Cash From Operations
-3975140
Capital Expenditures
10969
Cash From Investing
-10974
Cash From Financing
4627403
Net Change In Cash
640000
Cf_currency_symbol
USD
PE
-
PB
-0.0014981316824471957
ROE
71.02856680424051
ROA
-39.33933933933934
FCF
-3986109
Fcf Percent
-265.7406
Piotroski FScore
1
Health Score
31
Deep Value Investing Score
0.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
6.3
Garp Investing Score
2.5
Growth Investing Score
2.5
Momentum Investing Score
3.5
Net Net Investing Score
0.5
Quality Investing Score
2.5
Value Investing Score
2.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
15000
Quarters > 0 > income Statement > cost Of Revenue
0
Quarters > 0 > income Statement > gross Profit
15000
Quarters > 0 > income Statement > operating Expenses
5663000
Quarters > 0 > income Statement > operating Income
-5648000
Quarters > 0 > income Statement > interest Expense
649000
Quarters > 0 > income Statement > pretax Income
-8777000
Quarters > 0 > income Statement > net Income
-8777000
Quarters > 0 > income Statement > eps
-0.8534057569544742
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
10284674
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-7763000
Quarters > 0 > income Statement > operating Margin
-37653.333333333336
Quarters > 0 > income Statement > total Other Income Expense Net
-3129000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
7925000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
550000
Quarters > 0 > balance Sheet > inventories
61000
Quarters > 0 > balance Sheet > total Current Assets
12673000
Quarters > 0 > balance Sheet > property Plant Equipment
9580000
Quarters > 0 > balance Sheet > total Assets
22311000
Quarters > 0 > balance Sheet > payables
1369000
Quarters > 0 > balance Sheet > short Term Debt
2043000
Quarters > 0 > balance Sheet > long Term Debt
15785000
Quarters > 0 > balance Sheet > total Liabilities
34668000
Quarters > 0 > balance Sheet > equity
-12357000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-8777000
Quarters > 0 > cash Flow > depreciation
365000
Quarters > 0 > cash Flow > change In Working Capital
-420125
Quarters > 0 > cash Flow > cash From Operations
-3975140
Quarters > 0 > cash Flow > capital Expenditures
10969
Quarters > 0 > cash Flow > cash From Investing
-10974
Quarters > 0 > cash Flow > cash From Financing
4627403
Quarters > 0 > cash Flow > net Change In Cash
640000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.8534057569544742
Quarters > 0 > ratios > PB
-0.0014981316824471957
Quarters > 0 > ratios > ROE
71.02856680424051
Quarters > 0 > ratios > ROA
-39.33933933933934
Quarters > 0 > ratios > FCF
-3986109
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-265.7406
Quarters > 0 > health Score
31
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
27000
Quarters > 1 > income Statement > cost Of Revenue
366000
Quarters > 1 > income Statement > gross Profit
27000
Quarters > 1 > income Statement > operating Expenses
5891000
Quarters > 1 > income Statement > operating Income
-5864000
Quarters > 1 > income Statement > interest Expense
679000
Quarters > 1 > income Statement > pretax Income
-7419000
Quarters > 1 > income Statement > net Income
-7419000
Quarters > 1 > income Statement > eps
-0.7790127926521841
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
9523592
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-6374000
Quarters > 1 > income Statement > operating Margin
-21718.51851851852
Quarters > 1 > income Statement > total Other Income Expense Net
-1555000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
7285000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
1319000
Quarters > 1 > balance Sheet > inventories
79000
Quarters > 1 > balance Sheet > total Current Assets
11985000
Quarters > 1 > balance Sheet > property Plant Equipment
10082000
Quarters > 1 > balance Sheet > total Assets
22125000
Quarters > 1 > balance Sheet > payables
828000
Quarters > 1 > balance Sheet > short Term Debt
1387000
Quarters > 1 > balance Sheet > long Term Debt
15753000
Quarters > 1 > balance Sheet > total Liabilities
30675000
Quarters > 1 > balance Sheet > equity
-8550000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-7419000
Quarters > 1 > cash Flow > depreciation
366000
Quarters > 1 > cash Flow > change In Working Capital
-420000
Quarters > 1 > cash Flow > cash From Operations
-4744000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
2133000
Quarters > 1 > cash Flow > net Change In Cash
-2547000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.7790127926521841
Quarters > 1 > ratios > PB
-0.002004966736842105
Quarters > 1 > ratios > ROE
86.7719298245614
Quarters > 1 > ratios > ROA
-33.53220338983051
Quarters > 1 > ratios > FCF
-4744000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-175.7037037037037
Quarters > 1 > health Score
31
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
81000
Quarters > 2 > income Statement > cost Of Revenue
20000
Quarters > 2 > income Statement > gross Profit
61000
Quarters > 2 > income Statement > operating Expenses
4137000
Quarters > 2 > income Statement > operating Income
-4076000
Quarters > 2 > income Statement > interest Expense
608000
Quarters > 2 > income Statement > pretax Income
-751000
Quarters > 2 > income Statement > net Income
-751000
Quarters > 2 > income Statement > eps
-0.08510230350745007
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
8824673
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
261000
Quarters > 2 > income Statement > operating Margin
-5032.098765432099
Quarters > 2 > income Statement > total Other Income Expense Net
3325000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
9832000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
1511000
Quarters > 2 > balance Sheet > inventories
38000
Quarters > 2 > balance Sheet > total Current Assets
14671000
Quarters > 2 > balance Sheet > property Plant Equipment
10585000
Quarters > 2 > balance Sheet > total Assets
25314000
Quarters > 2 > balance Sheet > payables
1413000
Quarters > 2 > balance Sheet > short Term Debt
4106000
Quarters > 2 > balance Sheet > long Term Debt
12913000
Quarters > 2 > balance Sheet > total Liabilities
30287000
Quarters > 2 > balance Sheet > equity
-4973000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-751000
Quarters > 2 > cash Flow > depreciation
404000
Quarters > 2 > cash Flow > change In Working Capital
-3336000
Quarters > 2 > cash Flow > cash From Operations
-5011000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
2673000
Quarters > 2 > cash Flow > net Change In Cash
-2323000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.08510230350745007
Quarters > 2 > ratios > PB
-0.0031941305851598627
Quarters > 2 > ratios > ROE
15.101548361150211
Quarters > 2 > ratios > ROA
-2.9667377735640357
Quarters > 2 > ratios > FCF
-5011000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-61.864197530864196
Quarters > 2 > health Score
26
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
91000
Quarters > 3 > income Statement > cost Of Revenue
18000
Quarters > 3 > income Statement > gross Profit
73000
Quarters > 3 > income Statement > operating Expenses
8728000
Quarters > 3 > income Statement > operating Income
-8655000
Quarters > 3 > income Statement > interest Expense
516000
Quarters > 3 > income Statement > pretax Income
-13549000
Quarters > 3 > income Statement > net Income
-13549000
Quarters > 3 > income Statement > eps
-1.9483377726597981
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
6954133
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-12628000
Quarters > 3 > income Statement > operating Margin
-9510.989010989011
Quarters > 3 > income Statement > total Other Income Expense Net
-4894000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
12155000
Quarters > 3 > balance Sheet > short Term Investments
0
Quarters > 3 > balance Sheet > receivables
391000
Quarters > 3 > balance Sheet > inventories
68000
Quarters > 3 > balance Sheet > total Current Assets
16157000
Quarters > 3 > balance Sheet > property Plant Equipment
11122000
Quarters > 3 > balance Sheet > total Assets
27337000
Quarters > 3 > balance Sheet > payables
1240000
Quarters > 3 > balance Sheet > short Term Debt
1285000
Quarters > 3 > balance Sheet > long Term Debt
15426000
Quarters > 3 > balance Sheet > total Liabilities
36194000
Quarters > 3 > balance Sheet > equity
-8857000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-13549000
Quarters > 3 > cash Flow > depreciation
405000
Quarters > 3 > cash Flow > change In Working Capital
1637000
Quarters > 3 > cash Flow > cash From Operations
-4865000
Quarters > 3 > cash Flow > capital Expenditures
1000
Quarters > 3 > cash Flow > cash From Investing
-2000
Quarters > 3 > cash Flow > cash From Financing
2528000
Quarters > 3 > cash Flow > net Change In Cash
-2490000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-1.9483377726597981
Quarters > 3 > ratios > PB
-0.001413282081969064
Quarters > 3 > ratios > ROE
152.97504798464493
Quarters > 3 > ratios > ROA
-49.56286351830852
Quarters > 3 > ratios > FCF
-4866000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-53.472527472527474
Quarters > 3 > health Score
31
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
342000
Annuals > 0 > income Statement > cost Of Revenue
70000
Annuals > 0 > income Statement > gross Profit
272000
Annuals > 0 > income Statement > operating Expenses
33365000
Annuals > 0 > income Statement > operating Income
-33093000
Annuals > 0 > income Statement > interest Expense
4064000
Annuals > 0 > income Statement > pretax Income
-39400000
Annuals > 0 > income Statement > net Income
-39400000
Annuals > 0 > income Statement > eps
-5.665695493600712
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
6954133
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-33691000
Annuals > 0 > income Statement > operating Margin
-9676.315789473683
Annuals > 0 > income Statement > total Other Income Expense Net
-6307000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
12155000
Annuals > 0 > balance Sheet > short Term Investments
0
Annuals > 0 > balance Sheet > receivables
391000
Annuals > 0 > balance Sheet > inventories
68000
Annuals > 0 > balance Sheet > total Current Assets
16157000
Annuals > 0 > balance Sheet > property Plant Equipment
11122000
Annuals > 0 > balance Sheet > total Assets
27337000
Annuals > 0 > balance Sheet > payables
1240000
Annuals > 0 > balance Sheet > short Term Debt
1285000
Annuals > 0 > balance Sheet > long Term Debt
15426000
Annuals > 0 > balance Sheet > total Liabilities
36194000
Annuals > 0 > balance Sheet > equity
-8857000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-39400000
Annuals > 0 > cash Flow > depreciation
1645000
Annuals > 0 > cash Flow > change In Working Capital
3211000
Annuals > 0 > cash Flow > cash From Operations
-21326000
Annuals > 0 > cash Flow > capital Expenditures
15000
Annuals > 0 > cash Flow > cash From Investing
6316000
Annuals > 0 > cash Flow > cash From Financing
-1529000
Annuals > 0 > cash Flow > net Change In Cash
-16666000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-5.665695493600712
Annuals > 0 > ratios > PB
-0.001413282081969064
Annuals > 0 > ratios > ROE
444.84588461104215
Annuals > 0 > ratios > ROA
-144.12700735267222
Annuals > 0 > ratios > FCF
-21341000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-62.400584795321635
Annuals > 0 > health Score
30
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
654000
Annuals > 1 > income Statement > cost Of Revenue
121000
Annuals > 1 > income Statement > gross Profit
533000
Annuals > 1 > income Statement > operating Expenses
41073000
Annuals > 1 > income Statement > operating Income
-40540000
Annuals > 1 > income Statement > interest Expense
4558000
Annuals > 1 > income Statement > pretax Income
-49504000
Annuals > 1 > income Statement > net Income
-49504000
Annuals > 1 > income Statement > eps
-9.43483069468477
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
5246941
Annuals > 1 > income Statement > income Tax Expense
1537105
Annuals > 1 > income Statement > EBITDA
-43241000
Annuals > 1 > income Statement > operating Margin
-6198.7767584097855
Annuals > 1 > income Statement > total Other Income Expense Net
-8964000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
28821000
Annuals > 1 > balance Sheet > short Term Investments
6179000
Annuals > 1 > balance Sheet > receivables
1338000
Annuals > 1 > balance Sheet > inventories
37000
Annuals > 1 > balance Sheet > total Current Assets
38852000
Annuals > 1 > balance Sheet > property Plant Equipment
13431000
Annuals > 1 > balance Sheet > total Assets
52341000
Annuals > 1 > balance Sheet > payables
1504000
Annuals > 1 > balance Sheet > short Term Debt
20106000
Annuals > 1 > balance Sheet > long Term Debt
7152000
Annuals > 1 > balance Sheet > total Liabilities
38951000
Annuals > 1 > balance Sheet > equity
13390000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-49504000
Annuals > 1 > cash Flow > depreciation
1705000
Annuals > 1 > cash Flow > change In Working Capital
-191000
Annuals > 1 > cash Flow > cash From Operations
-30171000
Annuals > 1 > cash Flow > capital Expenditures
330000
Annuals > 1 > cash Flow > cash From Investing
-1499000
Annuals > 1 > cash Flow > cash From Financing
42163000
Annuals > 1 > cash Flow > net Change In Cash
10489000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-9.43483069468477
Annuals > 1 > ratios > PB
0.0007053393427931292
Annuals > 1 > ratios > ROE
-369.70873786407765
Annuals > 1 > ratios > ROA
-94.57977493742955
Annuals > 1 > ratios > FCF
-30501000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-46.637614678899084
Annuals > 1 > health Score
19
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
473000
Annuals > 2 > income Statement > cost Of Revenue
26000
Annuals > 2 > income Statement > gross Profit
447000
Annuals > 2 > income Statement > operating Expenses
48856000
Annuals > 2 > income Statement > operating Income
-48409000
Annuals > 2 > income Statement > interest Expense
3296000
Annuals > 2 > income Statement > pretax Income
-29918000
Annuals > 2 > income Statement > net Income
-29918000
Annuals > 2 > income Statement > eps
-9.176644736741208
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
3260233
Annuals > 2 > income Statement > income Tax Expense
-14639000
Annuals > 2 > income Statement > EBITDA
-25603000
Annuals > 2 > income Statement > operating Margin
-10234.460887949259
Annuals > 2 > income Statement > total Other Income Expense Net
18491000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
18332000
Annuals > 2 > balance Sheet > short Term Investments
4983000
Annuals > 2 > balance Sheet > receivables
2966000
Annuals > 2 > balance Sheet > inventories
43000
Annuals > 2 > balance Sheet > total Current Assets
29195000
Annuals > 2 > balance Sheet > property Plant Equipment
15240000
Annuals > 2 > balance Sheet > total Assets
44493000
Annuals > 2 > balance Sheet > payables
3014000
Annuals > 2 > balance Sheet > short Term Debt
6980000
Annuals > 2 > balance Sheet > long Term Debt
19253000
Annuals > 2 > balance Sheet > total Liabilities
41256000
Annuals > 2 > balance Sheet > equity
3237000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-29918000
Annuals > 2 > cash Flow > depreciation
1019000
Annuals > 2 > cash Flow > change In Working Capital
-1540000
Annuals > 2 > cash Flow > cash From Operations
-39011000
Annuals > 2 > cash Flow > capital Expenditures
5179000
Annuals > 2 > cash Flow > cash From Investing
-10164000
Annuals > 2 > cash Flow > cash From Financing
17249000
Annuals > 2 > cash Flow > net Change In Cash
-31956000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-9.176644736741208
Annuals > 2 > ratios > PB
0.0018129191844300277
Annuals > 2 > ratios > ROE
-924.2508495520544
Annuals > 2 > ratios > ROA
-67.24203807340481
Annuals > 2 > ratios > FCF
-44190000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-93.42494714587738
Annuals > 2 > health Score
16
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
723000
Annuals > 3 > income Statement > cost Of Revenue
289000
Annuals > 3 > income Statement > gross Profit
434000
Annuals > 3 > income Statement > operating Expenses
50412000
Annuals > 3 > income Statement > operating Income
-49978000
Annuals > 3 > income Statement > interest Expense
870000
Annuals > 3 > income Statement > pretax Income
-10168000
Annuals > 3 > income Statement > net Income
-9740000
Annuals > 3 > income Statement > eps
-3.1644716258333947
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
3077923
Annuals > 3 > income Statement > income Tax Expense
-428000
Annuals > 3 > income Statement > EBITDA
-8343000
Annuals > 3 > income Statement > operating Margin
-6912.586445366529
Annuals > 3 > income Statement > total Other Income Expense Net
39810000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
50288000
Annuals > 3 > balance Sheet > short Term Investments
0
Annuals > 3 > balance Sheet > receivables
1613000
Annuals > 3 > balance Sheet > inventories
41000
Annuals > 3 > balance Sheet > total Current Assets
54583000
Annuals > 3 > balance Sheet > property Plant Equipment
8422000
Annuals > 3 > balance Sheet > total Assets
63063000
Annuals > 3 > balance Sheet > payables
1923000
Annuals > 3 > balance Sheet > short Term Debt
493000
Annuals > 3 > balance Sheet > long Term Debt
14484000
Annuals > 3 > balance Sheet > total Liabilities
50466000
Annuals > 3 > balance Sheet > equity
12597000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-9740000
Annuals > 3 > cash Flow > depreciation
955000
Annuals > 3 > cash Flow > change In Working Capital
1003000
Annuals > 3 > cash Flow > cash From Operations
-34624000
Annuals > 3 > cash Flow > capital Expenditures
1332000
Annuals > 3 > cash Flow > cash From Investing
-1332000
Annuals > 3 > cash Flow > cash From Financing
27112000
Annuals > 3 > cash Flow > net Change In Cash
-8929000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-3.1644716258333947
Annuals > 3 > ratios > PB
0.0004398080019052155
Annuals > 3 > ratios > ROE
-77.3199968246408
Annuals > 3 > ratios > ROA
-15.44487258772973
Annuals > 3 > ratios > FCF
-35956000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-49.73167358229599
Annuals > 3 > health Score
15
Valuation > metrics > PE
-0.8534057569544742
Valuation > metrics > PB
-0.0014981316824471957
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
71.02856680424051
Profitability > metrics > ROA
-69.25747652489545
Profitability > metrics > Net Margin
-585.1333333333333
Profitability > final Score
40
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-8.702619414483822
Risk > final Score
-5
Risk > verdict
High
Liquidity > metrics > Current Ratio
3.7142438452520516
Liquidity > metrics > Quick Ratio
3.6963657678780772
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
40
Prev Profitabilities > 1
30
Prev Profitabilities > 2
40
Prev Risks > 0
-5
Prev Risks > 1
3
Prev Risks > 2
-37
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:36:45.600Z
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACan CLNNW stock double in the next year - Quarterly Investment Review & Weekly Consistent Profit Watchlists baoquankhu1.vn
Read more →Risk Off: Is CLNNW forming bullish engulfing patterns - July 2025 Weekly Recap & Intraday High Probability Alerts baoquankhu1.vn
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
* Institutions hold a combined 0.00% of the total shares of Clene Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.